Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| calbc:hasCorrelation | |
| skos:definition |
NCI: A chimeric monoclonal antibody with potential antineoplastic activity. Volociximab binds to and inhibits the activity of alpha(5)beta(1) integrin, thereby inhibiting endothelial cell-cell interactions, endothelial cell-matrix interactions, and angiogenesis. (NCI05),NCI: A monoclonal antibody that is being studied in the treatment of some types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Volociximab binds to a protein that is found on cells that line some tumor blood vessels. It is a type of angiogenesis inhibitor.,PDQ: A chimeric monoclonal antibody with potential antineoplastic activity. Volociximab binds to and inhibits the activity of alpha(5)beta(1) integrin, thereby inhibiting endothelial cell-cell interactions, endothelial cell-matrix interactions, and angiogenesis. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=415313&idtype=1" active clinical trials or "http://www.cancer.gov/Search/Clini
|
| skos:inScheme | |
| skos-xl:prefLabel | |
| skos-xl:altLabel |